SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the commercial launch of Herceptin® SC in Europe has triggered a $10 million milestone payment to Halozyme under the License and Collaboration Agreement between Halozyme and......
More...







